Skip to main content
. 2020 Apr 3;10:435. doi: 10.3389/fonc.2020.00435

Figure 9.

Figure 9

Effect of selected drug combinations and corresponding single drugs on ALL/CML cell lines or healthy PBMCs. Survival of CCRF-CEM or MOLT-4 cells (ALL), K-562 and KU812 cells (CML), or healthy PBMCs following single and combinatorial treatments at the dose of maximum selectivity. (A) ABT-199/lonidamine against ALL cells vs. PBMCs; (B) rotenone/2-deoxy-D-glucose against ALL/CML cells vs. PBMCs. (C,D) IACS-010759/vinorelbine or CCCP/dasatinib against CML cells vs. PBMCs. Shown are mean ± SEM from at least three independent biological replicates. Significance of changes in survival was assessed via Student's t-test. ***p < 0.001; **p < 0.01; ns: p > 0.05. Black stars or ns indicate comparison of ALL/CML cells vs. healthy PBMCs under the same treatment condition; purple stars indicate significantly lower survival under combinatorial treatment compared to single mitocan for each cell line; orange stars indicate significantly lower survival under combinatorial treatment compared to single complementary drug for each cell line.